Sugar Maple Asset Management LLC Buys New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Sugar Maple Asset Management LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 7,800 shares of the biopharmaceutical company's stock, valued at approximately $373,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company's stock worth $757,000 after buying an additional 252 shares during the last quarter. GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock valued at $50,000 after acquiring an additional 350 shares during the period. Juncture Wealth Strategies LLC grew its holdings in shares of Halozyme Therapeutics by 3.6% during the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company's stock valued at $690,000 after purchasing an additional 415 shares during the last quarter. Diversify Advisory Services LLC grew its holdings in shares of Halozyme Therapeutics by 8.5% during the third quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company's stock valued at $305,000 after purchasing an additional 418 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC raised its position in shares of Halozyme Therapeutics by 7.7% during the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company's stock worth $407,000 after purchasing an additional 507 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded up $1.14 during trading hours on Tuesday, hitting $55.94. The company had a trading volume of 1,204,214 shares, compared to its average volume of 1,646,401. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The firm has a market capitalization of $7.12 billion, a price-to-earnings ratio of 18.52, a PEG ratio of 0.42 and a beta of 1.24. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The firm's fifty day moving average is $49.50 and its 200 day moving average is $54.14.

Wall Street Analyst Weigh In

HALO has been the topic of several analyst reports. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a "buy" rating in a research note on Friday, January 10th. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler raised their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. JMP Securities upped their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a report on Friday, November 1st. Finally, Wells Fargo & Company dropped their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $60.89.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now owns 43,611 shares of the company's stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 2.70% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.